News coverage about Voyager Therapeutics (NASDAQ:VYGR) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.7643618112203 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several brokerages have issued reports on VYGR. BidaskClub raised Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Zacks Investment Research reissued a “sell” rating on shares of Voyager Therapeutics in a research note on Saturday. Morgan Stanley began coverage on Voyager Therapeutics in a research note on Friday, February 2nd. They issued an “overweight” rating on the stock. Canaccord Genuity reissued a “buy” rating and issued a $26.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, January 23rd. Finally, Chardan Capital reissued a “hold” rating and issued a $17.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $26.90.
Shares of Voyager Therapeutics (NASDAQ VYGR) traded up $0.17 during trading hours on Friday, hitting $18.18. The stock had a trading volume of 216,230 shares, compared to its average volume of 296,692. Voyager Therapeutics has a one year low of $8.10 and a one year high of $25.99. The firm has a market capitalization of $571.76, a price-to-earnings ratio of -6.40 and a beta of 4.04.
In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $13.63, for a total transaction of $74,828.70. Following the transaction, the insider now directly owns 10,983 shares of the company’s stock, valued at $149,698.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.00% of the stock is owned by corporate insiders.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.